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Abstract
Objectives: The connections of polymorphic variants of the gene of vasoactive hormones with the level of 
arterial pressure in pregnant women, depending on the development of preeclampsia (PE), have been studied. 
Materials and Methods: The study group included 382 pregnant women diagnosed with PE and 205 women with 
normal pregnancy. Polymorphisms of the endothelin-1 gene rs5370 (G>T EDN1) and guanine-binding protein 
β3 subunit gene rs2301339 (G>A GNB3) were studied by real-time polymerase chain reaction (PCR) of DNA 
synthesis (real-time PCR). Results: Women with PE with genotype TT EDN1 have lower values of systolic, 
diastolic, and mean arterial pressure at the end of pregnancy compared to those with G EDN1 allele (genotypes 
GG and GT, P = 0.01–0.04). Conclusions: Thus, as a result of this study, significant associations of genetic 
polymorphisms with blood pressure indicators in pregnant women with PE were established.
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INTRODUCTION
Recently, there has been a tendency to increase in the frequency of the pathological course of pregnancy, 
childbirth, the postpartum period in women, 
and perinatal morbidity and mortality in 
newborns.[1]
In this regard, the number of research devoted to 
molecular genetic studies of the complications 
of pregnancy has been constantly increasing.[2-4]
Preeclampsia (PE) is a complication of 
pregnancy, characterized by the development of 
endothelial dysfunction, multiple organ failure, 
disruption of coagulation and anticoagulation 
systems, microcirculation, metabolic processes, 
and immune response.[5]
According to the world literature and the WHO, 
the incidence of PE is 2–8%.[6,7] PE remains 
an important cause of maternal, perinatal, and 
neonatal morbidity and mortality.[7]
Severe PE and eclampsia cause the risk of 
complications such as hemorrhages and cerebral 
edema, placental abruption, disseminated 
intravascular coagulation syndrome, massive 
obstetric hemorrhages, HELLP syndrome, 
hemorrhage and rupture of the liver capsule, pulmonary 
edema, adult respiratory distress syndrome, and acute renal 
and hepatic insufficiency.[4,7]
According to a number of studies, this complication of 
pregnancy has a multifactorial nature.[3,8] Local gene networks 
of PE include endothelial dysfunction genes, vascular 
reaction genes, growth factor and cytokine genes, and major 
histocompatibility genes.[9-15]
MATERIALS AND METHODS
The study involved 587 women living in the territory 
of Central Russia (Belgorod region). The age of women 
ranged from 20 to 43 years (mean age 27.98 ± 4.50 years). 
Clinical and laboratory studies of women were conducted 
in the Perinatal Center of the Belgorod Regional Clinical 
Hospital (Department of Pathological Pregnancy). Criteria 
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for inclusion in the study group were (a) Russian nationality, 
(b) gestational age 37–40 weeks, and (c) informed consent 
for the study. Pregnant women with diabetes and liver or 
kidney failure, as well as pregnant women with diabetes 
with a gestation period of <37 weeks and over 40 weeks, 
were excluded from the study. Blood pressure was measured 
3 times according to the recommendations of the American 
Heart Association.[16] Data on blood pressure before 
pregnancy were obtained from case records of every woman. 
Mean blood pressure (MBP, mmHg) was calculated using 
the Hickam formula: MBP = (SBP + 2DBP)/3, where SBP 
is the systolic blood pressure and DBP is the diastolic blood 
pressure. Among 587 pregnant, 205 patients were with a 
physiological course of gestation and 382 women with a 
pregnancy complicated by PE.
PE was defined as the presence of hypertension, accompanied 
by proteinuria, as defined by a 24 h urine protein excretion 
more 300 mg.[17]
Molecular genetic methods
Venous blood (8–9 ml) was drawn from the ulnar vein of 
each woman. Genomic DNA was isolated using the method 
proposed Miller et al.[18] All women underwent typing of 
molecular genetic markers of endothelin-1 (G>T EDN1 
[rs5370]) and β3 subunits of guanine-binding protein 
(G>A GNB3 [rs2301339]).
The selection of polymorphisms was made in accordance 
with the criteria set forth in the paper by Ponomarenko.[19]
Loci genotyping was produced using real-time polymerase 
chain reaction (PCR) by the method of TaqMan probes 
detection according to relative fluorescence unit values of 
each probe on the thermocycler IQ5 with detecting system in 
real time. “Bio-Rad IQ5-Standart Edition” program was used 
for the alleles discrimination.
Statistical analysis
Allele frequencies of the genes polymorphism were estimated 
by the gene counting method, and the Chi-square test was 
used to identify significant departure from Hardy–Weinberg 
equilibrium. The distribution of allele and genotype frequencies 
between the study groups was compared by the Chi-square test 
for 2 × 2 contingency tables. The distribution of the quantitative 
traits such as SBP, DBP, MAP, and pulse pressure (the pressure 
difference between the systolic and diastolic pressures, PBP) 
before and at the end of pregnancy was analyzed by the Shapiro–
Wilks test. Since the values of the quantitative traits did not 
follow the normal distribution, median (Me) and interquartile 
range (Q25-Q75) were used for their description and intergroup 
comparisons were done using the Mann–Whitney U-test. All 
statistical analyses were performed using STATISTICA for 
Windows v. 6.0 (StatSoft, USA).
RESULTS
The biomedical and clinical characteristics of the study 
women are shown in Table 1.
As a result of studying the relationship of polymorphism 
of endothelin gene 1 G>T EDN1 rs5370 with BP levels in 
women at the end of pregnancy, significant associations were 
established only for pregnant women with PE [Table 2]. 
Women with PE with genotype TT EDN1 have lower values 
of systolic, diastolic, and mean arterial pressure at the end of 
pregnancy compared to those with G EDN1 allele (genotypes 
GG and GT, P = 0.01–0.04).
The study of the relationship between the polymorphism 
of the guanine-binding protein β3 subunit of rs2301339 and 
the blood pressure levels in pregnant women revealed no 
significant associations.
DISCUSSION
The results of this study suggest that G>T EDN1 rs5370 
polymorphism is associated with the level of arterial pressure 
in pregnant women with PE (37–40 weeks). The genotype TT 
EDN1 is associated with lower rates of systolic, diastolic, and 
MBP.
Gene EDN1 is located on the chromosome 06p24. The 
polymorphism studied is due to the replacement of guanine with 
thymine at position 5665 in exon 5 and leads to the replacement 
of the amino acid lysine with asparagine in the 198th codon of 
Table 1: The biomedical and clinical characteristics 
of the study women
Variables Value variables, Ме (Q25‑Q75)
Pregnant women 
without preeclampsia
Pregnant women 
with preeclampsia
Number 205 382
Age, year 26.7 (24.0–30.0) 27.2 (25.0–31.0)
Height, m 1.57 (1.54–1.60) 1.65 (1.62–1.68)
Weight, kg 70.0 (59.0–81.7) 79.3 (71.6–90.4)
BMI, kg/m2 23.0 (21.2–26.9) 29.2 (26.4–33.8)
SBP, mmHg 110.0 (110.0–120.0) 140.0 (135.0–150.0)
DBP, mmHg 70,0 (70.0–75.0) 90.0 (85.0–100.0)
PBP, mmHg 40.0 (40.0–40.0) 50.0 (50.0–60.0)
MAP, mmHg 85.0 (83.3–90.0) 106.7 (103.3–116.7)
∆MAP, mmHg 5.0 (0.0–10.0) 25.0 (20.0–35.0)
∆SBP, mmHg 0.0 (0.0–10.0) 20.0 (10.0–25.0)
∆DBP, mmHg 3.3 (0.0–8.3) 20.0 (13.3–28.3)
BMI: Body mass index, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure, PBP: Pulse blood pressure, 
MAP: Mean arterial pressure, Δ MAP: Change of mean 
arterial pressure, ΔSBP: Change of systolic blood pressure, 
ΔDBP: Change of diastolic blood pressure
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the polypeptide encoded by the gene (rs5370).[20] As some 
studies show, this polymorphism is associated with the plasma 
content of endothelin 1 in women during pregnancy.[21,22] It 
has been established that carriers of the allele T EDN1 have a 
higher level of endothelin 1 in the blood plasma compared to 
subjects with the genotype GG EDN1. In contrast, the study by 
Tanaka et al.[23] showed that plasma amounts of endothelin-1 in 
patients with essential hypertension do not differ in individuals 
with the allele T EDN1 and the genotype GG EDN1.[23]
Perhaps, the polymorphism of the gene EDN1 rs5370 is in 
close adherence to another SNP that provides an impact on 
blood pressure values.
The study conducted on the Mexican population has 
established the protective effect of this polymorphism on 
the development of PE.[24] Similar results were obtained in a 
study on the polish population.[25]
The observed inconsistency in the above results may be 
related to interpopulation and interethnic differences in the 
frequencies of alleles of polymorphism EDN1 rs5370.[26,27]
CONCLUSIONS
Thus, as a result of the study, the relationships of the genetic 
polymorphisms of vasoactive hormones with the level of 
blood pressure in women with PE were revealed. Women 
with genotypes GG and GT EDN1 (rs5370) have higher 
values of systolic, diastolic, and mean arterial pressure at the 
end of pregnancy.
Data obtained as a result of the research broaden the 
understanding of the mechanisms of preeclampsia 
development, and also allows prediction the nature of 
the clinical course of the disease, which will ensure the 
optimization of the treatment and diagnostic process for each 
patient.
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